Our Activities

We serve the public good by working to preserve existing treatments, develop new ones and increase affordable access to and use of vaccines and diagnostics to support appropriate use of antibiotics.

We lead and nurture the life sciences industry by leveraging private sector expertise and supporting innovative approaches to address antimicrobial resistance.

We operate with integrity; our members work in an ethical way and are committed to reducing environmental impact from the production of antibiotics.

We measure success by regularly reporting on the collective progress of our members. Our first progress report came out in January 2018. You can find it on our website.

Our second progress report will be released in early 2020. Stay tuned!

AMR Industry Alliance

Representing more than 100 biotechnology, diagnostics, generics and research-based pharmaceutical companies and associations, the AMR Industry Alliance is one of the largest private sector coalitions set up to provide sustainable solutions to the global antimicrobial resistance (AMR) crisis.

We drive progress in curbing AMR within the life sciences industry through a bold set of shared goals and commitments to improve access to high-quality antimicrobial products, invest in R&D, support appropriate use and minimize environmental risk. In particular, our members have committed to:

**access**
- Improve patient access to the most appropriate treatment, vaccine and diagnostic.
- Help remove substandard and falsified antimicrobial products from the market.
- Create an economic and regulatory environment that is supportive of a sustainable supply of quality-assured antibiotics.

**research & science**
- Invest in innovative antibiotics, vaccines, alternative technologies and diagnostics for resistant infections.
- Advocate for sustained investment in developing new technologies to combat AMR.
- Support stronger public-private collaboration and new ways of working to overcome the scientific challenges of creating new antimicrobials, vaccines, and diagnostics.

**appropriate use**
- Encourage infection prevention and control and expand use of diagnostics to ensure that antibiotics are only used for those patients who need them.
- Work with governments and others to educate healthcare professionals and patients on appropriate use.
- Collect and share surveillance data to better understand trends in resistance, inform appropriate use of antibiotics and vaccines and improve antimicrobial stewardship.

**manufacturing**
- Reduce environmental risk of manufacturing discharges by following a common risk assessment framework and a list of science-driven discharge concentration targets.
We are inclusive and welcome companies and associations from all over the world and from all parts of the life sciences industry: biotechnology, diagnostics, generics, and biopharmaceutical research. Whether you have a long history of tackling AMR or have only recently joined the fight, we will support you in your efforts and together build the momentum we need to find effective and sustainable solutions to curb AMR.

We foster collaboration by promoting knowledge sharing across traditional silos within the life sciences industry; and by serving as a platform for external engagement and advocacy.

We shape global dialogue by working closely with governments, health authorities and others to ensure a strong and consistent private sector presence in high-level political forums.

We give voice to the life sciences industry in national and international media. Through our website, press office and other communication channels, we shine a spotlight on the tangible steps our members are taking to address the global challenges of AMR.

For a full list of members:
www.amrindustryalliance.org/our-members

www.amrindustryalliance.org